AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Which passive funds are cheap for retirement? Focus on low-fee, diversified funds to maximize long-term growth with predictable costs.
23,256 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
U.S. regulators have cleared broader access to Anthropic’s Mythos model after a brief regulatory stand-off over safet...
As July 2026 begins, XRP hovers near $1.18 after a choppy June. Analysts say the price prediction July 2026 hinges on...
A chilling real-world scam shows how urgency and fear can drive seniors to hand over valuables. This guide breaks dow...
A ChatGPT-based forecast tied to Sam Altman envisions Bitcoin rising to $125K by end-2026, with a potential surge to ...
Hedge fund titan Ken Griffin challenges the AI hype, insisting the revolution is misunderstood and urging investors t...
Tesla could redefine AI profitability by owning the stack from hardware to the finished product. A new investment the...
SpaceX is exploring bold ways to run data centers in orbit, powered by solar energy. For NuScale Power investors, the...
The NEOS Nasdaq-100 High Income ETF (QQQI) currently yields almost 14%, drawing income seekers. But can this strategy...
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Pred secures a $2.5 million funding round led by ACCEL, aiming to deliver the fastest on-chain sports prediction trad...
Kratos Defense stock just surged after two new contract wins. This article breaks down what happened, why it matters,...